Proteomic dataset for altered glycoprotein expression upon GALNT3 knockdown in ovarian cancer cells

Razan Sheta; Florence Roux-Dalvai; Christina M Woo; Frédéric Fournier; Sylvie Bourassa; Carolyn R Bertozzi; Arnaud Droit; Dimcho Bachvarov

doi:10.1016/j.dib.2016.05.060

Proteomic dataset for altered glycoprotein expression upon GALNT3 knockdown in ovarian cancer cells

Data Brief. 2016 May 30:8:342-9. doi: 10.1016/j.dib.2016.05.060. eCollection 2016 Sep.

Authors

Razan Sheta¹, Florence Roux-Dalvai², Christina M Woo³, Frédéric Fournier², Sylvie Bourassa², Carolyn R Bertozzi⁴, Arnaud Droit⁵, Dimcho Bachvarov¹

Affiliations

¹ Department of Molecular Medicine, Laval University, Québec PQ, Canada; Centre de recherche du CHU de Québec, L'Hôtel-Dieu de Québec, Québec PQ, Canada.
² Centre de recherche du CHU de Québec, CHUL, Québec PQ, Canada.
³ Department of Chemistry, Stanford University, Stanford, CA, USA.
⁴ Department of Chemistry, Stanford University, Stanford, CA, USA; Howard Hughes Medical Institute, Stanford University, Stanford, CA, USA.
⁵ Department of Molecular Medicine, Laval University, Québec PQ, Canada; Centre de recherche du CHU de Québec, CHUL, Québec PQ, Canada.

Abstract

This article contains raw and processed data related to research published in "Role of the polypeptide N-acetylgalactosaminyltransferase 3 in ovarian cancer progression: possible implications in abnormal mucin O-glycosylation" [1]. The data presented here was obtained with the application of a bioorthogonal chemical reporter strategy analyzing differential glycoprotein expression following the knock-down (KD) of the GALNT3 gene in the epithelial ovarian cancer (EOC) cell line A2780s. LC-MS/MS mass spectrometry analysis was then performed and the processed data related to the identified glycoproteins show that several hundred proteins are differentially expressed between control and GALNT3 KD A2780s cells. The obtained data also uncover numerous novel glycoproteins; some of which could represent new potential EOC biomarkers and/or therapeutic targets.

Keywords: Ac4GalNAz labeling; GALNT3; Glycoproteomics; Glycosylation; Label free quantification; NetOGlyc and NetNGlyc prediction analysis.

Grants and funding

R01 CA200423/CA/NCI NIH HHS/United States